dexmethylphenidate (Focalin, Focalin XR) (cont.)

Pharmacy Author:
Medical and Pharmacy Editor:

GENERIC AVAILABLE: Yes

PREPARATIONS: Tablet: 2.5, 5, 10 mg. Capsules (extended-release) dexmethylphenidate: 5, 10, 15, 20, 25, 30, 35, and 40 mg

STORAGE: Store dexmethylphenidate between temperatures of 15 C to 30 C (59 F to 86 F).

PRESCRIBED FOR: Dexmethylphenidate is used for the treatment of attention deficit hyperactivity disorder (ADHD) in patients 6 years and older.

DOSING:

Adults:

  • The dose of immediate release tablets is 2.5 mg twice daily and increase by 2.5 or 5 mg weekly if needed. The maximum dose is 20 mg daily.
  • Methylphenidate-naive patients: Start with 10 mg extended release capsules by mouth once daily in the morning and adjust the dose weekly in 10 mg increments. The maximum dose is 40 mg daily.
  • Patients currently using methylphenidate: The starting dose of extended release capsules is one-half the total daily dose of methylphenidate. Patients currently taking immediate-release dexmethylphenidate tablets may be switched to same daily dose of extended-release capsules.

Children (ages 6 years and older):

  • The dose of immediate release tablets is 2.5 mg twice daily and increase by 2.5 or 5 mg weekly if needed. The maximum dose is 20 mg daily.
  • Methylphenidate-naive patients: The initial dose of extended release capsules is 5 mg by mouth once daily in the morning. The dose may be adjusted weekly in 5 mg increments if needed. The maximum dose is 30 mg daily.
  • Patients currently using methylphenidate: Initiate with one-half the total daily dose of methylphenidate. Patients currently taking immediate-release dexmethylphenidate tablets may be switched to same daily dose of extended-release capsules.

Safe and effective use of dexmethylphenidate is not established for children under 6 years of age.

DRUG INTERACTIONS: Dexmethylphenidate should not be combined with monoamine oxidase inhibitors (MAOIs) such as phenelzine (Nardil), selegiline (Zelapar, Emsam, and Eldepryl), tranylcypromine (Parnate), procarbazine (Matulane), rasagiline (Azilect), and isocarboxazid (Marplan) because of risks of hypertensive crisis. Dexmethylphenidate and MAO inhibitors should be separated by at least 14 days.

Medically Reviewed by a Doctor on 7/24/2014


Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Pill Finder Tool

Need help identifying pills and medications?
Use the pill identifier tool on RxList.


Back to Medications Index